Last reviewed · How we verify

NCT01091545: MBTST

Malmö Breast Tomosynthesis Screening Trial

Completed NA Last updated 13 November 2019
What this trial tests

NA trial testing DBT and FFDM in Breast Cancer in 15,000 participants. Completed in 30 September 2019.

Timeline
1 February 2010
Primary endpoint
31 December 2017
30 September 2019

Quick facts

Lead sponsorRegion Skane
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment15,000
Start date1 February 2010
Primary completion31 December 2017
Estimated completion30 September 2019
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Region Skane — full company profile →

Who can join

Adults 40 to 74, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare digital breast tomosynthesis (DBT) with full field digital mammography (FFDM) regarding effectiveness as screening modalities.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

Other Region Skane trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01091545.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing